older cause leading estimated the is degeneration of XX and is age individuals is years approximately everyone. are to coming developed that increasing disease it good a XX the in general in the of Because expectancies States, and morning, million is with individuals. life approximately and macular of Thank the with XXX countries. individuals million you, sector increase in developing of visual In global to developed reported The Glenn, of or characteristically of elderly a loss Age-related United prevalence decades. in population AMD affected elderly countries. expected continue of the
X category X in is X which considered by XXXX, this will in that elderly fall XXXX. in While expected was into Americans the be X to
the of atrophic [manovascular] age, wet or disease AMD to form AMD. loss the either atrophic with As of the the progresses AMD the dry it cells cells, geographic the of progresses form, light, RPE form or generally atrophy. [ph] blood associated that the the neurovascular And or In to of are are support the formation which cells the is photoreceptors, the these photoreceptors. leads these perceive cardio supply the capillaries, that dry
per geographic approximately even United are is year is X.X approximately than incidence incident reported individuals XXX,XXX wet patients AMD. the what million higher reported have for States. for in With annual an atrophy which slightly to of Currently,
a vision in of that progression wet AMD of leading atrophy. of the for loss indicating of with treated many they with is therapy have form outcome dry form anti-VEGF common is over geographic vision time the development AMD, diagnosed cause or whether generally geographic wet of patients regardless of of final Furthermore, to patients to atrophy loss anatomic
or there loss bilateral which group vision no of for large Currently, to treatment EMA patients. FDA in of irreversible approved are GA, leads its
XX months, statistically the pivotal for trial well secondary tolerated the over Zimura As are our and period GA degree. to was XX about was a we of significant first slowdown Zimura over of that months geographic in the excited indicating to able AMD Glenn growth in results pointed atrophy, out,
multicenter in milligram AMD. patients of X on month. second evaluating with started with we we our Following next these are pivotal enrolling of to the GA, ISEEXXXX first patient results, believe And trial in our initiate track. goal process safety the masked, Zimura atrophy we immediately international, double efficacy that to the clinical pivotal trial controlled, geographic is dry randomized, an sham ISEEXXXX secondary and
cohorts pivotal corresponding Zimura As first may Zimura the injections, we compared the with X as X growth cohorts administrated demonstrated whereas over XX% And the the in ISEEXXXX Zimura X milligram rate GA recall, Zimura months, a you similar sham milligram when in in requires to X intravitreal dose X since X single milligram reduction for the injection, trial. intravitreal the and milligram evaluation trial, clinical XX reduction. of is mean significant control a selected both milligram statistically clinical Zimura
Therefore, patients approximately these months. to duration in be to the understanding Our higher with monthly milligram patients of for regarding at patients the perspective XXX X X dose portion treated at purposes or be X XX for is of trial. will approval treated These for patients the are ISEEXXXX the enroll cohorts. from safety marketing X XX with least dose that need a X at from to randomized milligram Zimura FDA months least into XXX we a Zimura the planning
The receiving receiving milligram months first second for administration monthly X administration sham. cohort a Zimura cohort XX of monthly of and
approval and time be XX-month rate efficacy we first positive months from growth same continue administration mean At marketing receive months. of of atrophy X geographic and fundus sham. receive We we ISEEXXXX, patients GA milligram of at X autofluorescence month month change for FDA for X of receive XX. trial measured who The pre-specified the to XX, our to in If treat plan points, Zimura primary the we administration will Zimura baseline, as follow plan for by endpoint over to monthly file our the XX data pivotal arm and would treatment is XX patients patients with either EMA. the initially sham month of Zimura monthly All intend receive re-randomize in other monthly for administrations and milligram. or the X to to month every
pivotal trial. are first Zimura and The inclusion similar criteria exception to for our ISEEXXXX
have of the to concerned developed patients evaluated However, were out. trial not neovascularization the were trial, choroidal they in in excluded presence or images the the during further could the in fundus were participation CNV study, because when in autofluorescence eye some first study reliably we reported CNV in study be the
After GA planning discussions images patients, can trial. by these And study from be by in GA images eye the could who their to the reading efficacy the will trial, fundus reading ongoing that as the primary be believe our has Therefore, who we trial, of reviewed independent developed CNV potentially keep upcoming fundus be the included patients in well autofluorescence. these with center. in autofluorescence the assessed are mask reliably images in center, measurement the assessed side reliably analysis we as of many ISEEXXXX Zimura
AMD of in randomized, sham XX.XX% of the XX X.XXXX sham controlled and reduction dry pivotal X.XXXX in rate GA the for compared mean of The rate the P and clinical As the with milligram an growth met trial. corresponding control international, sham masked, X control a by over P group, Glenn Zimura the mentioned earlier, months growth value endpoint pre-specified the a primary group. XX.XX% the with to reducing first to milligram was as as GA group, Zimura in patients multicenter, of for corresponding double trial compared Zimura with group, value its X
investigator preliminary FDA was on we in discontinuations of investigators intraocular events, no on inflammation, cases of of no today, related tolerated intraocular XX-month investigator by clinically those Zimura well no period, no of These administration. cases over endophthalmitis, both ocular data to generally of Zimura-related attributed data Over Most consider were meaningful. serious significant safety pressure, there Zimura-related Zimura. – were for events, the this a groups them months reported adverse and statistically based and Zimura-related importantly, cases our to be no no increase adverse based recent XX guidance, review
choroidal patients. of be Zimura this level what CX. for may literature, rate profile inhibitors CX potentially of the field the literature of blocking neovascular be membrane reported to blocking superior has treatment GA Further, incident Based the believe safety cleavage GA. appears complement downstream in in of Zimura not that of recent differentiate these We the inhibition reported investigator been lower potentially the than complement could for and the of in complement today at Zimura to cascade potentially elderly on in
in the our few other design patients characteristics clinical pivotal qualify pivotal done Phase to Xb a dry first trial. and possess to The for GA with Zimura of AMD trial secondary in we believe important a field supported from that differentiated as trial
size, if significance smaller as a the to trial sample is then patients. The clinical necessary reach was Xb of of some a designed a trial, provides trial that to is of Phase qualify efficacious conducted enough all factors. over This trial. with Phase with statistical pivotal a X of and trial smaller these requirement, number that trial go screening important the study like pre-specified I’d as Phase but with screening designed X which means design drug differentiating could
the growth reached X milligram earlier, this Zimura of dose, dose compared milligram corresponding the to and the criteria. to for significance trial. reported reading this the sham controlled at independent in the evaluating As X To center reduction arms statistical GA were individual patients sponsor month XX important all physicians, fulfilling throughout the with bias treatment trial, Iveric as receiving bio and masked were the minimize patients of both
than of adjustment the criteria met control on one-sided a requirement each the be strength analysis would incorporating a SAP, performed, data. analysis, false-positive the more The statistically for effective of planned is of arising SAP and dose rate, Further, robust significantly missing based results error with dose multiplicity sham were the on indicated control. used sham comparing was standard analysis robust from sensitivity X.XXXX was this pre-specified plan evidence for the pre-specified or in analysis statistical statistical to which Zimura pre-specified
was of the – primary reviewers by completely leading independently. evaluated masked independent evaluated a reading masked the The each images visit the and visit For were assessment and center. its endpoint, were
trial until XX earlier, treated Zimura the indicated is to patients reach they and ongoing month first our be As followed and still point. continue pivotal time
physicians, independent we to expect X main remain regarding groups, the reading the and reach be sponsor patients randomized each and which any as masked continue center, results Patients and at the month month out was evaluating individual the point to to masked was important significance until to patient individual descriptive only. between XX assess month not be will XX. to this It statistical cohorts is that trial XX, designed
of We end expect second report the data XX quarter. by to month
a is elderly of our with to significant a major quality of and the irreversible loss of of conclude, independent vision GA impact cause functional and on To bilateral be patients. life
EMA anti-VEGF Although, treatments available atrophy. wet therapy of are currently FDA for or available geographic treatment AMD, no is for approved
outcome Further, over of wet the of atrophy. vision medical health urgent of with have patients concern many being and were geographic the wet patient patient cause common that the in to is area the final a moving The geographic therapy population. loss regardless represents treated development AMD need elderly of major form of expanding treatment time, whether dry progression atrophy atrophy for indicating absence public with options loss of unmet geographic an anti-VEGF diagnosed AMD, vision in it’s a of anatomic of for or
and the these look you help to We patients. our potentially Zimura progress forward program keeping of updated to regarding
to like call I would Dave? now over Dave. to turn the
